TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement

GSK plc's subsidiary TESARO has sued AnaptysBio alleging a material breach of their 2014 collaboration and exclusive license covering PD‑1 antibody dostarlimab (Jemperli), seeking the right to terminate the current license, secure a perpetual irrevocable license to dostarlimab and reduce royalties and milestone payments to AnaptysBio by 50%. The dispute follows AnaptysBio's August 2020 breach notice that purported to revoke PD‑1 rights and an October 2020 amendment that increased AnaptysBio's royalties after GSK acquired TESARO in 2019; GSK and TESARO state AnaptysBio's earlier allegations are without merit. Shares moved modestly on the report (GSK -0.50% to $46.11; ANAB +1.76% to $37.66), and the litigation introduces legal and commercial uncertainty around Jemperli's rights and future royalty flows.

Analysis

GSK plc's subsidiary TESARO has filed litigation against AnaptysBio alleging a material breach of their 2014 collaboration and exclusive license for PD-1 antibody dostarlimab (marketed as Jemperli), seeking the right to terminate the current license, obtain a perpetual irrevocable license to dostarlimab and reduce royalties and milestone payments to AnaptysBio by 50%. The dispute follows AnaptysBio's August 2020 breach notice that purported to revoke PD-1 rights and a subsequent October 2020 amendment that increased AnaptysBio's royalties after GSK acquired TESARO in 2019; Jemperli received FDA approval in 2021. GSK and TESARO assert AnaptysBio's earlier allegations are without merit, introducing a direct legal contest over IP and commercial economics tied to Jemperli.

The immediate market reaction was muted but differentiated: GSK shares closed at $46.11 down 0.50% while ANAB closed at $37.66 up 1.76%, and available signals rate the story as moderately negative with a market impact score of 0.35 and per-ticker sentiment modestly favorable to GSK (0.2) and negative for ANAB (-0.6). The litigation centers on intellectual property and contractual interpretation and therefore creates binary outcomes that could materially alter future royalty flows, cash receipts and valuation assumptions for AnaptysBio. Thematically this is a Legal & Litigation/Patents issue within Healthcare and reflects post-acquisition contract renegotiation dynamics.

Investor-relevant risk is concentrated in the potential for protracted, value-impacting litigation; a GSK win could permanently reduce ANAB's royalty stream while a favorable ruling for AnaptysBio could preserve or enhance its expected revenues from Jemperli. Absent further public filings or settlement announcements, near-term volatility and headline sensitivity should be expected for both tickers, with ANAB especially exposed to downside from an adverse legal outcome.

Key Decisions for Investors

• Monitor court filings, SEC disclosures and company statements as primary near-term catalysts and reassess positions on any material legal developments
• Reduce or hedge exposure to AnaptysBio pending resolution given the explicit claim to cut royalties by 50% and the negative sentiment signal
• Consider maintaining or modestly increasing GSK exposure on weakness since the litigation, if GSK obtains a perpetual license and lower payments that would improve its economics, but size positions conservatively until legal outcome becomes clearer
• Watch for disclosures on Jemperli royalty receipts and any amendment or settlement terms, which will be the decisive inputs for revaluing both companies